Barron\'s - 22.07.2019

(C. Jardin) #1

July22,2019 BARRON’S M7


The Striking Price


Options


A Beyond Meat Earnings Play


By Steven M. Sears


AFTER RISING SO DRAMATICALLY SO QUICKLY,


Beyond Meat ’s stock is so well done that


investorsmightbeforgivenforconcluding


there’s no juice left in the trade.


Theplant-basedproteincompany’sstock


was priced at $25 in its early May initial


public offering, opened at $46, and then


traded as high as $201.88. The stock is up


some580%atitscurrentprice,whichmakes


the stock market’s almost 20% return this


year seem like small beer.


Yetinvestorsremainunusuallybullishon


BeyondMeatstock(ticker:BYND),whichis


tradingaround$177aheadofthecompany’s


release of second-quarter earnings on July


29. The sentiment is fairly incredible at a


timewhenmostinvestorsareafraidoftheir


ownshadowsandsitarounddebatingwhat


may happen to stock prices after the Fed-


eralReserve’srate-settingcommitteemeets


at month’s end.


“BeyondMeatisthenew Tesla [TSLA]


andthemarket’slatestcultstock,”Michael


Schwartz,Oppenheimer&Co.’schiefoptions


strategist, told Barron’s.


To be sure, Beyond Meat is a different


kindofstockatpreciselytherighttime.In-


vestors want a new theme to focus on so


theydon’thavetothinkaboutalloftheold-


worldworries,likeeconomicdataandtrade


wars.Theurgetoescapeissopowerfulthat


investorsareevenwillingtoforgetthatjus-


tifying a $168 stock price for Beyond Meat


usingadiscounted-cash-flowanalysismeans


modeling $4.9 billion in 2029 sales, rather


than the $3.5 billion currently assumed by


JPMorgan’s Ken Goldman.


“Is $5 billion in sales in 10 years out of


thequestion?No,butit’snotlikely,either,in


ourview,”Goldmanwroteinarecentclient


report.“Similarly,wecouldmodel2029gross


marginincreasingto43.3%versusthe35.5%


weexpect;this,toowouldleadto$168.But


the food group’s median is only 29%.”


Thoughthevaluationargumentprompted


GoldmantogivethestockaNeutralrating—


whichmightbeinterpretedasindicatingthe


bankistellingclientstosellthestockitjust


tookpublic—theoppositeistrue.Inthenear


term,hetoldclientsheis“increasinglyopti-


mistic” on the stock and he would trade it.


The last time Beyond Meat reported


earnings, in early June, the stock surged,


rising some 100% and pushing above $200.


Ontheearningscall,thecompany’smanage-


mentsaid2019full-yearsaleswouldbe$210


million, about 2% higher than Wall Street


wasexpecting—andthattriggeredabuying


stampedethatisestimatedtohavecostthe


legion of short sellers aligned against the


stock as much as $1 billion.


It’simpossibletoknowwhatwillhappen


when the company next reports. Most sea-


sonedinvestorsadmittradingearningscan


be like flipping a coin. But if you are com-


fortable with risk and volatility, Beyond


Meat is a must-trade ahead of earnings.


Whenthestockwasaround$172.99,JP-


Morgan’s derivatives strategist, Shawn


Quigg, recommended investors consider


buyingBeyondMeat’s$175calloptionsthat


expire Aug. 2 for $10.30. (Calls increase in


valuewhentheunderlyingsecuritypricein-


creases.)Ifthestockisat$210atexpiration,


thecallisworth$35.Ofcourse,ifthestock


expires below the call strike price, the


money spent on the call is lost.


The stock has since rallied above the


strike price. Investors who think the stock


willrallyhighercouldconsiderbuyingcalls


that are slightly above the current stock


price and that expire Aug. 2.


Tastytrade, an options education website,


recently launched Quiet Foundation, a free


onlinerisk-analysisprogram.Werecognize


theironyofmentioningriskmanagementin


thiscolumn.Butanincreasedawarenessof


risk unites all investors.


Investors who upload their portfolio to


thewebsitegetareportthatevaluateskey


risk factors, including portfolio diversifica-


tion,theprobabilityoflossesorgainswithin


ayear,howwelltheirinvestmentsfaredrel-


ative to the S&P 500 index, and how much


riskwasassumedrelativetothebenchmark.


Other measures focus on net opportunity


value,whichidentifiesvolatilepositions—and


even position liquidity—which could prove


critical if the Fed startles markets.


Equity Options


CBOE VOLATILITY INDEX


VIX Close VIX Futures

10


15


20


25


30


35


40


A SO NDJ FMAM J J

Daily Values Source: CBOE

THE EQUITY-ONLY PUT-CALL RATIO


Put-Call Ratio S&P 500 Index

50


80


110


140


170


200


230


260


A SO NDJ FMAM J J

Source: McMillan Analysis Corp.

SPX SKEW


Implied volatility %

7


8


9


10


11


12


13%


A SO NDJ FMAM J J

Source: Credit Suisse Equity Derivatives Strategy

NDX SKEW


Implied volatility %

8


9


10


11%


A SO NDJ FMAM J J

Source: Credit Suisse Equity Derivatives Strategy

Skew indicates whether the options market expects a stock-market advance or decline. It measures the difference
between the implied volatility of puts and calls that are 10% out of the money and expire in three months. Higher
readings are bearish.

Week'sMostActive


Company Symbol TotVol Calls Puts AvgTotVol IV%ile Ratio

Blue Apron APRN^1050916161143480312471 33.6


Alexco Resource AXU^2306223670156100 14.8
First Horizon National FHN 17913 16755 1158 1460 18 12.3

Big Lots BIG 31942 23679 8263 3348 88 9.5


Eagle Bancorp EGBN^24411362107925694 9.5


JB Hunt JBHT^334511554017911404454 8.3
Domino's Pizza DPZ 59706 31146 28560 7504 14 8.0

WPX Energy WPX 83359 65865 17494 10424 52 8.0


Jagged Peak JAG^491675484164092 7.7


Cintas CTAS^1330957507559177633 7.5
Fortuna Silver Mines FSM 18255 16976 1279 2636 97 6.9

CSX Corp. CSX 182122 97034 85088 28572 13 6.4


Gain Capital GCAP 6271 5464 807 996 94 6.3


Skecher's SKX^7955248354311981348097 5.9
Texas Capital Bancshares TCBI 5820 1190 4630 992 24 5.9

Textron TXT 13737 8531 5206 2344 27 5.9


Range Resources Corp. RRC 134688 29624 105064 23972 99 5.6


PetMed Express PETS^238631281111052440498 5.4
Galapagos GLPG 2465 1366 1099 468 15 5.3

Thistableofthemostactiveoptionsthisweek,ascomparedto average weeklyactivity–notjustrawvolume.Theideaisthatthe
unusuallyheavytradingintheseoptionsmightbeapredictorofcorporateactivity–takeovers,earningssurprises,earningspre-
announcements,biotechFDAhearingsordrugtrialresultannouncements,andsoforth.Dividendarbitragehasbeeneliminated.In
short,thislistattemptstoidentifywhereheavyspeculationistakingplace. Theseoptionsarelikelytobeexpensiveincomparisonto
theirusualpricinglevels.Furthermore,manyofthesesituationsmayberumor-driven.Mostrumorsdonotprovetobetrue,soone
shouldbeawareoftheseincreasedrisksiftradinginthesenames
RatioistheTotVoldividedbyAvgTotVol.IV%ileishowexpensivetheoptionsareonascalefrom0to100.

Source:McMillanAnalysis

Free download pdf